Synthesis and biological activities of 2α-chloro-1-epicalcitriol and 1-epicalcitriol

Anomalous diequatorial epoxide ring opening of 1β,2β-oxido-cholesta-5,7-diene-3β,25-diol 1 produces the 1β-hydroxy-2α-chloro-provitamin 2 and its corresponding 1β-hydroxy-provitamin 3. The provitamins 2 and 3 are transformed by irradiation and thermal isomerization to 2α-chloro-1-epicalcitriol NS3 (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Steroids 1998, Vol.63 (1), p.28-36
Hauptverfasser: Schönecker, Bruno, Reichenbächer, Manfred, Gliesing, Sabine, Gonschior, Manuela, Griebenow, Sirid, Scheddin, Dietmar, Mayer, Hubert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Anomalous diequatorial epoxide ring opening of 1β,2β-oxido-cholesta-5,7-diene-3β,25-diol 1 produces the 1β-hydroxy-2α-chloro-provitamin 2 and its corresponding 1β-hydroxy-provitamin 3. The provitamins 2 and 3 are transformed by irradiation and thermal isomerization to 2α-chloro-1-epicalcitriol NS3 ( 4) and 1-epicalcitriol NS8 ( 5), respectively. These two A-ring derivatives were tested for their in vitro biological activity in the mesenchymal, murine cell line C3H10T 1 2 , and their effects were compared with those of the native vitamin D 3 derivatives 25(OH)D 3 and 1,25(OH) 2D 3. NS3 and NS8 showed marked differences in their affinity for the vitamin D binding protein (DBP) and in their ability to inhibit cell proliferation. NS8 has the ability to bind to a high-affinity DBP-binding site for which 25(OH)D 3 has none affinity. The 2α-chloro-substitution ( NS3) prevents binding to the postulated noncompetitive, NS8-specific DBP-binding site and diminishes the affinity to the vitamin D receptor (VDR) and therefore diminishing NS3’s biological abilities. The elucidation of the structure-function relationships at the DBP-binding-sites could have major impact on the development of new vitamin D 3 derivatives with extended serum half-life.
ISSN:0039-128X
1878-5867
DOI:10.1016/S0039-128X(97)00106-2